[go: up one dir, main page]

WO2009032123A3 - Dérivés d'indole tétracycliques et procédés pour les utiliser - Google Patents

Dérivés d'indole tétracycliques et procédés pour les utiliser Download PDF

Info

Publication number
WO2009032123A3
WO2009032123A3 PCT/US2008/010147 US2008010147W WO2009032123A3 WO 2009032123 A3 WO2009032123 A3 WO 2009032123A3 US 2008010147 W US2008010147 W US 2008010147W WO 2009032123 A3 WO2009032123 A3 WO 2009032123A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating
indole derivatives
tetracyclic indole
viral infections
preventing viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/010147
Other languages
English (en)
Other versions
WO2009032123A2 (fr
Inventor
Frank Bennett
Qingbei Zeng
Srikanth Venkatraman
Mousumi Sannigrahi
Kevin X Chen
Gopinadhan N Anilkumar
Stuart B Rosenblum
Joseph A Kozlowski
F George Njoroge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US12/675,277 priority Critical patent/US20110104109A1/en
Priority to CN200880113543A priority patent/CN101842376A/zh
Priority to CA2697451A priority patent/CA2697451A1/fr
Priority to MX2010002316A priority patent/MX2010002316A/es
Priority to EP08795628A priority patent/EP2197884A2/fr
Priority to JP2010522933A priority patent/JP5179585B2/ja
Application filed by Schering Corp filed Critical Schering Corp
Priority to AU2008295483A priority patent/AU2008295483B2/en
Publication of WO2009032123A2 publication Critical patent/WO2009032123A2/fr
Publication of WO2009032123A3 publication Critical patent/WO2009032123A3/fr
Priority to ZA2010/01391A priority patent/ZA201001391B/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des dérivés d'indole tétracycliques, des compositions comprenant au moins un dérivé d'indole tétracyclique, et des procédés d'utilisation des dérivés d'indole tétracycliques pour traiter ou prévenir une infection virale ou une affection liée à un virus chez un patient.
PCT/US2008/010147 2005-07-13 2008-08-27 Dérivés d'indole tétracycliques et procédés pour les utiliser Ceased WO2009032123A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CN200880113543A CN101842376A (zh) 2007-08-29 2008-08-27 四环吲哚衍生物及其用于治疗或预防病毒感染
CA2697451A CA2697451A1 (fr) 2007-08-29 2008-08-27 Derives d'indole tetracycliques et procedes pour les utiliser
MX2010002316A MX2010002316A (es) 2007-08-29 2008-08-27 Derivados tetraciclicos de indol y su uso para el tratamiento o prevencion de infecciones virales.
EP08795628A EP2197884A2 (fr) 2007-08-29 2008-08-27 Dérivés d'indole tétracycliques et procédés pour les utiliser
JP2010522933A JP5179585B2 (ja) 2007-08-29 2008-08-27 四環系インドール誘導体およびその使用法
US12/675,277 US20110104109A1 (en) 2005-07-13 2008-08-27 Tetracyclic indole derivatives and their use for treating or preventing viral infections
AU2008295483A AU2008295483B2 (en) 2007-08-29 2008-08-27 Tetracyclic indole derivatives and their use for treating or preventing viral infections
ZA2010/01391A ZA201001391B (en) 2007-08-29 2010-02-25 Tetracyclic indole derivatives and their use for treating or preventing viral infections

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96868407P 2007-08-29 2007-08-29
US60/968,684 2007-08-29

Publications (2)

Publication Number Publication Date
WO2009032123A2 WO2009032123A2 (fr) 2009-03-12
WO2009032123A3 true WO2009032123A3 (fr) 2009-06-11

Family

ID=40319417

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/010147 Ceased WO2009032123A2 (fr) 2005-07-13 2008-08-27 Dérivés d'indole tétracycliques et procédés pour les utiliser

Country Status (11)

Country Link
EP (1) EP2197884A2 (fr)
JP (1) JP5179585B2 (fr)
KR (1) KR20100061819A (fr)
CN (1) CN101842376A (fr)
AR (1) AR068109A1 (fr)
AU (1) AU2008295483B2 (fr)
CA (1) CA2697451A1 (fr)
MX (1) MX2010002316A (fr)
TW (1) TW200918536A (fr)
WO (1) WO2009032123A2 (fr)
ZA (1) ZA201001391B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8063072B2 (en) 2009-09-21 2011-11-22 Roche Palo Alto Llc Heterocyclic antiviral compounds

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2240481A1 (fr) 2008-01-11 2010-10-20 Albany Molecular Research, Inc. Pyridoindoles (1-azinone)-substitués en tant qu'antagonistes mch
MX2010013630A (es) * 2008-06-13 2010-12-21 Schering Corp Derivados triciclicos de indol y metodos de uso de los mismos.
ES2383273T3 (es) 2008-07-23 2012-06-19 F. Hoffmann-La Roche Ag Compuestos heterocíclicos antivíricos
AU2009295981A1 (en) 2008-09-26 2010-04-01 F. Hoffmann-La Roche Ag Pyrine or pyrazine derivatives for treating HCV
BRPI1016167A2 (pt) 2009-04-25 2019-07-16 Hoffmann La Roche compostos heterocíclicos antivirais.
CA2763140A1 (fr) 2009-05-29 2010-12-02 Schering Corporation Composes antiviraux de trois fractions d'aryle liees pour traiter des maladies telles que l'hepatite c
TWI428332B (zh) 2009-06-09 2014-03-01 Hoffmann La Roche 雜環抗病毒化合物
MX2011012541A (es) 2009-06-24 2012-08-03 Hoffmann La Roche Compuestos heterociclicos antivirales.
US8629158B2 (en) 2009-07-01 2014-01-14 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
WO2011003021A1 (fr) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Antagonistes de mch-1 azabicycloalcane-indoles et azabicycloalcane-pyrrolo-pyridines substitués par azinone, leurs procédés de fabrication et leur utilisation
US8618299B2 (en) 2009-07-01 2013-12-31 Albany Molecular Research, Inc. Azinone-substituted azapolycycle MCH-1 antagonists, methods of making, and use thereof
JP2012532144A (ja) 2009-07-01 2012-12-13 アルバニー モレキュラー リサーチ， インコーポレイテッド アジノン置換アゼピノ［ｂ］インドールおよびピリド−ピロロ−アゼピンｍｃｈ−１拮抗薬、ならびにその作製方法および使用
JP2013512246A (ja) 2009-11-25 2013-04-11 メルク・シャープ・アンド・ドーム・コーポレーション ウイルス疾患治療に有用な縮合型三環式化合物およびその誘導体
US20130156731A1 (en) 2009-12-22 2013-06-20 Kevin X. Chen Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas
PH12012501748A1 (en) 2010-03-09 2012-11-12 Merck Sharp & Dohme Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
CN102858547A (zh) 2010-05-02 2013-01-02 Xjet有限公司 带有自清洗、防沉积与除烟气装置的打印系统
US20140377223A1 (en) 2010-07-26 2014-12-25 Joseph A. Kozlowski Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
EP2621932A4 (fr) * 2010-09-29 2014-03-26 Merck Sharp & Dohme Composés hétérocycliques tétracycliques pour le traitement d'une infection par le virus de l'hépatite c
EP2621279B1 (fr) 2010-09-29 2018-04-04 Merck Sharp & Dohme Corp. Dérivés tétracycliques condensés et procédés d'utilisation de ceux-ci dans le traitement de maladies virales
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
WO2012088038A2 (fr) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Antagonistes de mch-1 consistant en tétrahydro-carbolines substituées par pipérazinone, leurs procédés de fabrication et utilisations
US9156872B2 (en) 2011-04-13 2015-10-13 Merck Sharp & Dohme Corp. 2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
CA2832459A1 (fr) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. Derives de nucleoside 2'-substitues et procedes d'utilisation de ceux-ci pour le traitement de maladies virales
WO2013033900A1 (fr) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Composés hétérocycliques tétracycliques et leurs procédés d'utilisation pour le traitement de maladies virales
WO2013033901A1 (fr) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Dérivés benzofuranes substitués par un hétérocycle et leurs procédés d'utilisation pour le traitement de maladies virales
WO2013033899A1 (fr) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Composés benzofuranes substitués et leur procédés d'utilisation pour le traitement de maladies virales
US20140378416A1 (en) 2011-09-14 2014-12-25 Michael P. Dwyer Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases
US9457039B2 (en) 2012-10-17 2016-10-04 Merck Sharp & Dohme Corp. 2′-disubstituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
AR092959A1 (es) 2012-10-17 2015-05-06 Merck Sharp & Dohme Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
WO2014059901A1 (fr) 2012-10-17 2014-04-24 Merck Sharp & Dohme Corp. Dérivés nucléosides à substitution 2'-cyano et leurs méthodes d'utilisation pour le traitement de maladies virales
US9732111B2 (en) 2012-11-19 2017-08-15 Merck Sharp & Dohme Corp. 2′-alkynyl substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
EP3010512B1 (fr) 2013-06-18 2017-12-27 Merck Sharp & Dohme Corp. Dérivés de nucléosides cycliques à substitution phosphonate et leurs méthodes d'utilisation pour le traitement de maladies virales
WO2014205592A1 (fr) 2013-06-24 2014-12-31 Merck Sharp & Dohme Corp. Composés hétérocycliques et leurs procédés d'utilisation pour le traitement de l'hépatite c
WO2014205593A1 (fr) 2013-06-24 2014-12-31 Merck Sharp & Dohme Corp. Composés de benzofurane substitués et leurs méthodes d'utilisation pour le traitement de maladies virales
EP3063140A4 (fr) 2013-10-30 2017-11-08 Merck Sharp & Dohme Corp. Pseudopolymorphes d'un inhibiteur de la protéine ns5a du vhc et leurs utilisations
US10899788B2 (en) 2016-06-20 2021-01-26 Merck Sharp & Dohme Corp. Cyclic phosphate substituted nucleoside compounds and methods of use thereof for the treatment of viral diseases
CN112898312B (zh) * 2021-01-29 2021-11-12 湖南南新制药股份有限公司 一种稠合多环吡啶酮衍生物及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006020082A1 (fr) * 2004-08-09 2006-02-23 Bristol-Myers Squibb Company Inhibiteurs de replication du hcv
WO2006034337A2 (fr) * 2004-09-23 2006-03-30 Wyeth Derives de carbazole et de cyclopentaindole destines a traiter une infection par le virus de l'hepatite c
WO2007029029A2 (fr) * 2005-09-09 2007-03-15 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Derives d'indole tetracycliques utilises comme agents antiviraux
WO2007038209A2 (fr) * 2005-09-23 2007-04-05 Schering Corporation Antagonistes du mglur1 tetracycliques fusionnes utilises en tant qu'agents therapeutiques

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006020082A1 (fr) * 2004-08-09 2006-02-23 Bristol-Myers Squibb Company Inhibiteurs de replication du hcv
WO2006034337A2 (fr) * 2004-09-23 2006-03-30 Wyeth Derives de carbazole et de cyclopentaindole destines a traiter une infection par le virus de l'hepatite c
WO2007029029A2 (fr) * 2005-09-09 2007-03-15 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Derives d'indole tetracycliques utilises comme agents antiviraux
WO2007038209A2 (fr) * 2005-09-23 2007-04-05 Schering Corporation Antagonistes du mglur1 tetracycliques fusionnes utilises en tant qu'agents therapeutiques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
R. SILVESTRI ET AL.: "Synthesis and biological evaluation of 5H-indolo [3,2-b][1,5]benzothiazepine derivatives, designed as conformationally constrained analogues of the human immunodeficiency virus type 1 reverse transcriptase inhibitor L-737126", ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, vol. 9, no. 2, 1998, pages 139 - 148, XP002523406 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8063072B2 (en) 2009-09-21 2011-11-22 Roche Palo Alto Llc Heterocyclic antiviral compounds

Also Published As

Publication number Publication date
WO2009032123A2 (fr) 2009-03-12
MX2010002316A (es) 2010-03-22
CA2697451A1 (fr) 2009-03-12
EP2197884A2 (fr) 2010-06-23
JP5179585B2 (ja) 2013-04-10
AU2008295483B2 (en) 2013-11-21
JP2010537980A (ja) 2010-12-09
KR20100061819A (ko) 2010-06-09
TW200918536A (en) 2009-05-01
AR068109A1 (es) 2009-11-04
CN101842376A (zh) 2010-09-22
ZA201001391B (en) 2010-11-24
AU2008295483A1 (en) 2009-03-12

Similar Documents

Publication Publication Date Title
WO2009032123A3 (fr) Dérivés d'indole tétracycliques et procédés pour les utiliser
MX2010002317A (es) Derivados de indol sustituidos y metodos para su utilizacion.
MX2010002319A (es) Derivados indolicos 2,3 sustituidos para el tratamiento de infecciones virales.
MX2010005356A (es) Derivados de indol 3-heterociclico sustituidos y metodos de uso de los mismos.
MX2010002318A (es) Derivados azaindol 2,3-sustituidos para tratar infecciones virales.
MX2010005355A (es) Derivados de indol sustituidos con 3-aminosulfonilo y metodos de uso de los mismos.
WO2008136815A3 (fr) Dérivés indoliques annelés à cycle à 5 ou 6 éléments et leurs méthodes d'utilisation
TW200833662A (en) 4,5-ring annulated indole derivatives and methods of use thereof
WO2008127364A3 (fr) Composés antiviraux et utilisation de ceux-ci
WO2008115281A3 (fr) Composés de traitement d'infections virales
WO2010062821A8 (fr) Composés antiviraux, compositions, et procédés d’utilisation
WO2010014134A8 (fr) Composés et compositions pharmaceutiques pour le traitement d'infections virales
IL250858A0 (en) Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections
MX2009011533A (es) Productos quimicos, composiciones y metodos para tratamiento y prevencion de infecciones de virus orthopox y enfermedades asociadas.
IL187135A0 (en) 2-amido-6-amino-8-oxopurine derivatives as toll-like receptor modulators for the treatment of cancer and viral infections, such as hepatitis c
AP2010005480A0 (en) Small molecule inhibitors for the treatment or prevention of denque virus infection.
WO2009129246A3 (fr) Compositions et leurs procédés de préparation et d'utilisation
MX2012011222A (es) Compuestos y composiciones farmaceuticas para el tratamiento de infecciones virales.
WO2009105513A3 (fr) Nouveaux composés et procédés pour la thérapie
WO2009149179A3 (fr) Procédés et dispositifs améliorés de thérapie antivirale
WO2011049988A3 (fr) Indazoles pour traiter une infection par le virus flaviviridae
WO2011158039A8 (fr) Dérivés d'uréido-pyrazole destinés à être utilisés dans le traitement d'infections par un rhinovirus
WO2011160024A3 (fr) Composés utiles en tant qu'agents antiviraux, compositions, et procédés d'utilisation
WO2008017346A3 (fr) Utilisation de dérivés d'acide ascorbique pour la fonctionnalisation de matrices
WO2009071689A3 (fr) Dérivés d'oxindole substitués par halogène en position 5 et leur utilisation pour traiter des maladies liées à la vasopressine

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880113543.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08795628

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 583388

Country of ref document: NZ

Ref document number: 2008295483

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 204053

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 12010500407

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2697451

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2010522933

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/002316

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008295483

Country of ref document: AU

Date of ref document: 20080827

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PI 2010000803

Country of ref document: MY

ENP Entry into the national phase

Ref document number: 20107006704

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008795628

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12675277

Country of ref document: US